Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of INVAC-1 immunogenicity
NCT04515043Phase 1Completed
- Sponsor
- Invectys
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INVAC-1 in solid tumor, sponsored by Invectys. Primary endpoint: Long term anti telomerase specific memory responses. Started Oct 2020; status: completed.
02
Drugs
INVAC-1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04515043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515043.